

General information about company	
Scrip code	524396
Name of company	BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED
Result Type	Main Format
Class of security	Equity
Date of start of financial year	01-04-2016
Date of end of financial year	31-03-2017
Date of board meeting when results were approved	30-05-2017
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	22-05-2017
Description of presentation currency	INR
Level of rounding used in financial results	Lakhs
Reporting Quarter	Yearly
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited	Audited
Segment Reporting	Multi segment
Description of single segment	
Start time of board meeting	16:00
End time of board meeting	17:00

Financial Results – Other than Bank			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-01-2017	01-04-2016
B	Date of end of reporting period	31-03-2017	31-03-2017
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Revenue From Operations		
	Revenue from operations	198.03	918.44
	Other income	435.66	440.79
	Total Revenue	633.69	1359.23
2	Expenses		
(a)	Cost of materials consumed	30.22	90.41
(b)	Purchases of stock-in-trade	330.93	762.02
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	16.03	-1.32
(d)	Employee benefit expense	25.4	53.22
(e)	Finance costs	5.11	16.36
(f)	Depreciation and amortisation expense	8.85	28.42
(g)	Other Expenses		
1	Manufacturing Expenses	15.07	85.63
2	Administration Expenses	18.53	58.43
3	Selling and Distribution Expenses	31.63	35.02
	Total other expenses	65.23	179.08
	Total expenses	481.77	1128.19

Financial Results – Other than Bank			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-01-2017	01-04-2016
B	Date of end of reporting period	31-03-2017	31-03-2017
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
3	Profit before exceptional and extraordinary items and tax	151.92	231.04
4	Exceptional items	-1.62	-1.62
5	Profit before extraordinary items and tax	150.3	229.42
6	Extraordinary items	0	0
7	Profit before tax	150.3	229.42
	Current tax	50	50
	Deferred tax	0	0
	Total tax expenses	50	50
9	Net Profit Loss for the period from continuing operations	100.3	179.42
10	Profit (loss) from discontinuing operations before tax	0	0
11	Tax expense of discontinuing operations	0	0
12	Net profit (loss) from discontinuing operation after tax	0	0
13	Profit (loss) for period before minority interest	100.3	179.42
16	Net profit (Loss) for the period	100.3	179.42

Financial Results – Other than Bank			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-01-2017	01-04-2016
B	Date of end of reporting period	31-03-2017	31-03-2017
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
17	Details of equity share capital		
	Paid-up equity share capital	1627.38	1627.38
	Face value of equity share capital	10	10
17	Details of debt securities		
18	Reserves excluding revaluation reserve		-733.93
20	Earnings per equity share		
	Basic earnings (loss) per share from continuing and discontinued operations	0.62	1.1
	Diluted earnings (loss) per share from continuing and discontinued operations	0.62	1.1
24	Disclosure of notes on financial results	Textual Information(1)	

Text Block	
Textual Information(1)	<ul style="list-style-type: none"> • The above audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 30th Day of May , 2017 The figures of last quarter are the balancing figures between audited figures in respect of the full financial year and published year to date figure up to third quarter of the current financial year • Previous year period's/year's figures have been regrouped wherever necessary to conform to the current period's classification. • The Company has reported segment wise information as per Accounting Standard (AS-17). The Operations of the company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments <ol style="list-style-type: none"> 1. Pharma Product 2. Chemicals Division 3. Plastic Division <p>The aforesaid audited financial Results will be uploaded on the Company's website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors</p>

Statement of Asset and Liabilities		
Particulars	Current year ended (dd-mm-yyyy)	Previous year ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2016	01-04-2015
Date of end of reporting period	31-03-2017	31-03-2016
Whether results are audited or unaudited	Audited	Audited
Nature of report standalone or consolidated	Standalone	Standalone
Equity and liabilities		
1 Shareholders' funds		
Share capital	1627.38	1627.38
Reserves and surplus	-357.725	-536.704
Money received against share warrants	0	0
Total shareholders' funds	1269.655	1090.676
2 Share application money pending allotment	0	0
3 Deferred government grants	0	0
4 Minority interest		
5 Non-current liabilities		
Long-term borrowings	0	0
Deferred tax liabilities (net)	0	0
Foreign currency monetary item translation difference liability account	0	0
Other long-term liabilities	0	0
Long-term provisions	0	0
Total non-current liabilities	0	0
6 Current liabilities		
Short-term borrowings	142.809	136.998
Trade Payables		
(A) Total outstanding dues of micro enterprises and small enterprises	709.522	1159.184
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	0	0
Other current liabilities	0	0
Short-term provisions	62.052	26.336
Total current liabilities	914.383	1322.518
Total equity and liabilities	2184.038	2413.194
Assets		
1 Non-current assets		
(i) Fixed assets		
Tangible assets	916.453	897.553
Producing properties	0	0
Intangible assets	0	0
Preproducing properties	0	0
Tangible assets capital work-in-progress	0	0
Intangible assets under development or work-in-progress	0	0
Total fixed assets	916.453	897.553

Statement of Asset and Liabilities			
Particulars		Current year ended (dd-mm-yyyy)	Previous year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2016	01-04-2015
Date of end of reporting period		31-03-2017	31-03-2016
Whether results are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
(ii)	Non-current investments	0	0
(v)	Deferred tax assets (net)	0	0
(vi)	Foreign currency monetary item translation difference asset account	0	0
(vii)	Long-term loans and advances	0	0
(viii)	Other non-current assets	0	0
Total non-current assets		916.453	897.553
Current assets			
	Current investments	0	0
	Inventories	16.623	9.602
	Trade receivables	1146.441	1398.463
	Cash and cash equivalents	7.488	6.772
	Bank balance other than cash and cash equivalents	23.485	11.31
	Short-term loans and advances	44.799	52.098
	Other current assets	28.749	37.396
Total current assets		1267.585	1515.641
Total assets		2184.038	2413.194
Disclosure of notes on assets and liabilities			

Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-01-2017	01-04-2016
Date of end of reporting period		31-03-2017	31-03-2017
Whether accounts are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
1	Segment Revenue		
	(net sale/income from each segment should be disclosed)		
1	Pharma Unit	662.49	1205.08
2	Chemicals Division	41.23	139.08
3	Plastic Division	0.28	1.281
4	Other	-70.3	13.794
	Total segment revenue	633.7	1359.235
	Less: Inter segment revenue		
	Revenue from operations	633.7	1359.235
2	Segment Result		
	Profit (+) / Loss (-) before tax and interest from each segment		
1	Pharma Unit	156	252.24
2	Chemicals Division	-29.57	-21.46
3	Plastic Division	6.72	-7.26
4	Other	19.84	19.84
	Total Profit before tax	152.99	243.36
	i. Finance cost		
	ii. Other unallocable expenditure net off unallocable income		
	Profit before tax	152.99	243.36
3	Capital Employed		
	(Segment Asset - Segment Liabilities)		
1	Pharma Unit	606.63	606.63
2	Chemicals Division	735.97	735.97
3	Plastic Division	-72.95	-72.95
4	Other	0	0
	Total capital employed	1269.65	1269.65
	Disclosure of notes on segments		

